logo-loader
viewDyadic International Inc

Zacks analyst John Vandermosten bullish on Dyadic International's C1 gene expression platform

Zacks Small Cap Research Senior Biotechnology Analyst John Vandermosten talks to Proactive Investors about his most recent report on Florida-based biotech company Dyadic International Inc (NASDAQ:DYAI).

Vandermosten says Dyadic's most recent collaboration with VTT, a contract research organization, has extended its contract together, to develop its gene expression platform called C1.

Quick facts: Dyadic International Inc

Price: 8.76 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $240.63 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Dyadic paves the way for patients to gain access to low-cost...

Dyadic (NASDAQ) President and CEO Mark Emalfarb joined Steve Darling from Proactive Vancouver with news the company continues to very busy even with the COVID-19 crisis. Emalfarb discussing what the company is doing with other partners to help battle the virus.  Emalfarb also telling...

on 1/4/20

2 min read